比利时生物技术公司TiGenix公司已经融资共1370万美元用于支持其正处于三期研究的干细胞疗法研究项目Cx601。根据这次融资协议，投资方Kreos Capital公司将在四年内完成这次投资。首先Kreos Capital将于明年的二月份第一次投资690万美元，而第二笔共计340万美元投资预计在五月份到位。最后的340万美元将在明年九月份到账。而整个Cx601的研究项目预计持续四年。Cx601主要是用于治疗克罗恩氏病患者的肛周瘘管。 而就在上个月，公司刚刚通过股市融资1640万美元。公司CEO Eduardo Bravo在声明中表示这次融资使公司获得充足的研究经费，有利于公司更好的独立的进行Cx601三期临床研究。

详细英文报道：

Belgium's TiGenix has hauled in about $13.7 million in debt financing, piling up cash as it works through Phase III with a stem cell treatment.

Under the four-year deal, financier Kreos Capital will pay out $6.9 million in February, $3.4 million in May and another $3.4 million by September, the companies said, giving TiGenix the money it needs to advance Cx601 through late-stage trials. The treatment combats complex perianal fistulas in Crohn's disease patients, eradicating growths that worsen incontinence at a better rate that current therapies, TiGenix said.

The latest raise follows a $16.4 million stock sale last month, and the cash infusion will help TiGenix push its pipeline of cell therapies, which includes a Phase II treatment for rheumatoid arthritis and a Phase I autoimmune disease drug.

"In combination with the recent strategic investment ... this funding significantly strengthens our financial position and allows us to aggressively expand our pipeline of proprietary cell therapy products," CEO Eduardo Bravo said in a statement. "Importantly, it enables us to independently finalize the Phase III trial with our lead product Cx601 and file for European registration, and thus capture significantly more value from a potential partnering agreement."

Today's TiGenix is the result of a 2011 merger with Spain's Cellerix. Cx601 is a holdover from the Spanish company, and TiGenix derives most of its revenue from ChondroCelect, an on-the-market regenerative therapy for knee cartilage.